The advent of ATTR-specific drugs, though pricey, is enabling better survival in these overlapping diseases, researchers say.

Amvuttra is the first and only RNA interference (RNAi) therapeutic approved by the EC for both the cardiomyopathy and the ...

Heart failure often follows heart attacks, diabetes, or high blood pressure. However, a very different cause is being ...

Four blue-chip stocks are trading near their 52-week lows and offering investors incredible entry points and huge dividends.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild ...

Many artists at any age simply cannot live without a stage. But after 70 years it is already very difficult to work, said ...

The interim data, with a cutoff date of April 11, 2025, showed an impressive 70% CR rate. Prior to NXC-201 treatment, the ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Early Phase I results for JNJ-79635322 demonstrated an 86.1% overall response rate in heavily pretreated multiple myeloma ...

Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the European Commission (EC) to treat adults with ...